SG11201903283UA - Methods and compositions for tusc2 immunotherapy - Google Patents
Methods and compositions for tusc2 immunotherapyInfo
- Publication number
- SG11201903283UA SG11201903283UA SG11201903283UA SG11201903283UA SG11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- tusc2
- therapy
- english
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 abstract 2
- 102100036129 Tumor suppressor candidate 2 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 101150026353 CD46 gene Proteins 0.000 abstract 1
- 241000218691 Cupressaceae Species 0.000 abstract 1
- 101150000195 EGR3 gene Proteins 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 101100383058 Mus musculus Cd59b gene Proteins 0.000 abstract 1
- 101100181103 Mus musculus Klra5 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407329P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056338 WO2018071668A1 (en) | 2016-10-12 | 2017-10-12 | Methods and compositions for tusc2 immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903283UA true SG11201903283UA (en) | 2019-05-30 |
Family
ID=61906060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903283UA SG11201903283UA (en) | 2016-10-12 | 2017-10-12 | Methods and compositions for tusc2 immunotherapy |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11278592B2 (he) |
| EP (1) | EP3525809A4 (he) |
| JP (3) | JP7041136B2 (he) |
| KR (1) | KR102661905B1 (he) |
| CN (2) | CN116672456A (he) |
| AU (2) | AU2017342364B2 (he) |
| BR (1) | BR112019007365A2 (he) |
| CA (1) | CA3040458A1 (he) |
| CL (1) | CL2019001002A1 (he) |
| IL (1) | IL265965A (he) |
| MA (1) | MA46542A (he) |
| RU (1) | RU2755903C2 (he) |
| SG (1) | SG11201903283UA (he) |
| WO (1) | WO2018071668A1 (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3138555T (pt) | 2014-04-30 | 2020-12-15 | Fujifilm Corp | Composição lipossómica e método de produção da mesma |
| CN112334140A (zh) * | 2018-06-20 | 2021-02-05 | 富士胶片株式会社 | 包含内含吉西他滨的脂质体组合物及免疫检查点抑制剂的组合医药 |
| CN116121194B (zh) * | 2023-02-27 | 2023-10-24 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种肺癌免疫治疗耐药细胞系及其制备方法和应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4162282A (en) | 1976-04-22 | 1979-07-24 | Coulter Electronics, Inc. | Method for producing uniform particles |
| US4310505A (en) | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4728575A (en) | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
| US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| IL79559A0 (en) | 1986-07-29 | 1986-10-31 | Univ Ramot | Contrast agents for nmr medical imaging |
| US4728578A (en) | 1986-08-13 | 1988-03-01 | The Lubrizol Corporation | Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5397987A (en) | 1993-03-03 | 1995-03-14 | Rheometrics, Inc. | Method and apparatus for analyzing samples using nuclear magnetic resonance |
| AU7326594A (en) | 1993-07-09 | 1995-02-06 | Synergen, Inc. | Recombinant ctla4 polypeptides and methods for making the same |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| DE69708919T2 (de) | 1996-08-19 | 2002-06-27 | Us Gov Nat Inst Health | Neue liposomkomplexe mit erhöhter systemischer verabreichung |
| DE69735241T2 (de) | 1996-11-21 | 2006-11-02 | Promega Corp., Madison | Alkyl peptidamide für topische verwendung |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CZ303703B6 (cs) | 1998-12-23 | 2013-03-20 | Pfizer Inc. | Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| DK1325125T3 (da) | 2000-07-10 | 2013-09-08 | Univ Texas | Tumorundertrykkende gener af chromosomerne 3P21.3 |
| EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| EP1424998B1 (en) | 2001-08-16 | 2010-05-26 | The Trustees of The University of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
| MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
| PT1648507T (pt) | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| ATE531733T1 (de) | 2005-01-06 | 2011-11-15 | Novo Nordisk As | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| AU2006220500A1 (en) | 2005-03-09 | 2006-09-14 | Board Of Regents, The University Of Texas System | Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes |
| WO2007149062A2 (en) | 2005-03-14 | 2007-12-27 | Board Of Regents, The University Of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| US20110052570A1 (en) | 2005-10-26 | 2011-03-03 | Children's Medical Center Corporation | Method to prognose response to anti-egfr therapeutics |
| WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
| CA2649955C (en) | 2006-05-09 | 2013-04-02 | Colgate-Palmolive Company | Oral care regimen |
| JP5478261B2 (ja) | 2007-01-11 | 2014-04-23 | ノヴォ ノルディスク アクティーゼルスカブ | 抗ｋｉｒ抗体、製剤、およびその使用 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| WO2010065939A1 (en) | 2008-12-05 | 2010-06-10 | Indiana University Research & Technology Corporation | Combination therapy to enhace nk cell mediated cytotoxicty |
| BR112012007875A2 (pt) | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| IN2012DN02753A (he) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| ES2826894T3 (es) | 2010-02-19 | 2021-05-19 | Xencor Inc | Nuevas inmunoadhesinas CTLA4-IG |
| US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
| TWI664191B (zh) | 2010-11-22 | 2019-07-01 | 天賜製藥公司 | Ｎｋ細胞調節治療及治療血液惡性疾病之方法 |
| US20120244209A1 (en) * | 2011-03-02 | 2012-09-27 | Roth Jack A | Tusc2 therapies |
| CN103717619B (zh) | 2011-05-25 | 2018-11-13 | 因内特制药股份有限公司 | 治疗发炎及自体免疫疾病之抗-kir抗体 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
| ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
| US20130247924A1 (en) | 2012-03-23 | 2013-09-26 | Mark Scatterday | Electronic cigarette having a flexible and soft configuration |
| WO2013148158A1 (en) * | 2012-03-30 | 2013-10-03 | President And Fellows Of Harvard College | Laser-actuated therapeutic nanoparticles |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR20210104166A (ko) | 2013-06-25 | 2021-08-24 | 백시넥스 인코포레이티드 | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 |
| CA2917858A1 (en) | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170246298A1 (en) * | 2014-09-24 | 2017-08-31 | Apellis Pharmaceuticals, Inc. | Methods and compositions for cancer treatment and treatment selection |
-
2017
- 2017-10-12 US US16/341,134 patent/US11278592B2/en active Active
- 2017-10-12 CN CN202310535801.7A patent/CN116672456A/zh active Pending
- 2017-10-12 CA CA3040458A patent/CA3040458A1/en active Pending
- 2017-10-12 CN CN201780076886.XA patent/CN110072540B/zh active Active
- 2017-10-12 SG SG11201903283UA patent/SG11201903283UA/en unknown
- 2017-10-12 EP EP17861125.7A patent/EP3525809A4/en active Pending
- 2017-10-12 JP JP2019519701A patent/JP7041136B2/ja active Active
- 2017-10-12 BR BR112019007365A patent/BR112019007365A2/pt unknown
- 2017-10-12 AU AU2017342364A patent/AU2017342364B2/en active Active
- 2017-10-12 MA MA046542A patent/MA46542A/fr unknown
- 2017-10-12 RU RU2019114031A patent/RU2755903C2/ru active
- 2017-10-12 WO PCT/US2017/056338 patent/WO2018071668A1/en unknown
- 2017-10-12 KR KR1020197013556A patent/KR102661905B1/ko active IP Right Grant
-
2019
- 2019-04-11 IL IL265965A patent/IL265965A/he unknown
- 2019-04-12 CL CL2019001002A patent/CL2019001002A1/es unknown
-
2022
- 2022-02-17 US US17/674,800 patent/US20220168388A1/en active Pending
- 2022-03-10 JP JP2022037295A patent/JP2022081616A/ja active Pending
-
2023
- 2023-03-15 AU AU2023201601A patent/AU2023201601A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025307A patent/JP2024057000A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110072540B (zh) | 2023-06-02 |
| CA3040458A1 (en) | 2018-04-19 |
| JP2024057000A (ja) | 2024-04-23 |
| CL2019001002A1 (es) | 2019-11-08 |
| KR102661905B1 (ko) | 2024-04-29 |
| JP2022081616A (ja) | 2022-05-31 |
| KR20190067216A (ko) | 2019-06-14 |
| US11278592B2 (en) | 2022-03-22 |
| JP2019534268A (ja) | 2019-11-28 |
| BR112019007365A2 (pt) | 2019-07-09 |
| EP3525809A4 (en) | 2020-06-03 |
| US20220168388A1 (en) | 2022-06-02 |
| JP7041136B2 (ja) | 2022-03-23 |
| AU2017342364A1 (en) | 2019-05-23 |
| AU2023201601A1 (en) | 2023-04-13 |
| AU2017342364B2 (en) | 2022-12-15 |
| CN110072540A (zh) | 2019-07-30 |
| WO2018071668A1 (en) | 2018-04-19 |
| CN116672456A (zh) | 2023-09-01 |
| RU2019114031A3 (he) | 2020-11-13 |
| IL265965A (he) | 2019-06-30 |
| MA46542A (fr) | 2021-03-31 |
| EP3525809A1 (en) | 2019-08-21 |
| RU2019114031A (ru) | 2020-11-13 |
| US20200038480A1 (en) | 2020-02-06 |
| RU2755903C2 (ru) | 2021-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201900442PA (en) | Sorting of t lymphocytes in a microfluidic device | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |